Loading page...
Log inCreate account
Loading page...
This round is closed. The next round and similar open calls are listed below. Synced from the EU Funding & Tenders Portal on 9 November 2026.
This call is closed. These open or upcoming calls fund the closest work.
Based on projects the EU funded on the same subject in this programme.
SPHERE-AfricaSTRENGTHENING PUBLIC HEALTH EDUCATION IN RESEARCH & EPIDEMIOLOGY IN AFRICA (SPHERE-AFRICA)
HORIZON-JU-GH-EDCTP3-2025-02-FELLOW-01-two-stage · 2026 · Official record ↗
EpiScientia NetworkAfrican National Public Health Institutes (NPHIs) Network of Training In Integrated Health Informatics And Data Sciences, Scaling Up Infectious Disease Modelling.
HORIZON-JU-GH-EDCTP3-2025-02-FELLOW-01-two-stage · 2026 · Official record ↗
FORTRESS-SSAFOSTERING OUTBREAK RESILIENCE THROUGH TRAINING, RESEARCH, EPIDEMIOLOGY, AND STATISTICAL SCIENCE TO STRENGTHEN THE SUB-SAHARAN AFRICA PUBLIC HEALTH WORKFORCE
HORIZON-JU-GH-EDCTP3-2025-02-FELLOW-01-two-stage · 2026 · Official record ↗
RER-CTOReinforce the Ethical and Regulatory Ecosystem for the Transformation of Clinical Trials Oversight in Ethiopia, Tanzania and beyond
HORIZON-JU-GH-EDCTP3-2023-01-05 · 2024 · Official record ↗
GREAT-LIFELinking Infectious disease Front-liners’ control Efforts with central public health authorities in The African Great Lakes Region
HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03 · 2023 · Official record ↗
CTCANClinical Trials Community Africa Network
HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04 · 2023 · Official record ↗
The PHM HubA Public Health Modelling & Data Science Fellowship Centre of Excellence in West and Central Africa
HORIZON-JU-GH-EDCTP3-2025-02-FELLOW-01-two-stage · 2026 · Official record ↗
CAPACITY 2023CONSORTIUM FOR DEVELOPING REGULATORY CAPACITY FOR CLINICAL TRIALS USING GENE THERAPY PRODUCTS AND STRENGTHENING PHARMACOVIGILANCE IN THE CONDUCT OF CLINICAL TRIALS IN EAST AFRICA
HORIZON-JU-GH-EDCTP3-2023-01-05 · 2024 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
Projects funded under this topic should contribute towards the reduction of the burden of disease in sub-Saharan Africa and thus contribute to achieving SDG 3 ‘Ensure healthy lives and promote well-being for all at all ages’ through increased international cooperation among researchers and funders, catalyse research synergies, and leverage resources and investment.
Proposals are expected to include the effective in-kind and/or financial contribution of contributing partners, in order to produce more meaningful and significant effects enhancing the impact of the related research activities.
Applicant consortium
The contributions from contributing partners should correspond to the amounts they have committed in the letter of endorsement requesting to become a contributing partner (Article 9 Council Regulation (EU) 2021/2085[1]). Their contributions can consist of financial contributions and/or in-kind contributions. Applicant contributing partners must submit a first draft of the endorsement letter to the Programme Office before the deadline for submission of the second-stage applications[2]. For details on the process on becoming a Global Health EDCTP3 contributing partner, please consult the Guide for contributing partners.
In case of in-kind contribution (even combined with financial contribution), contributing partners become a part of the applicant consortium and participate in the project, as appropriate i.e. as beneficiaries or affiliated entities in the meaning of Article 8 of the Horizon Europe model grant agreement. Also, Global Health EDCTP3 contributing partners can be a country, an international organisation or any public or private legal entity, other than the Global Health EDCTP3 members or their constituent or affiliated entities, please consult the Guide for contributing partners.
Background
Despite the shifting global health research funding landscape and resources increasingly being re-focused to other emerging (health) priorities, HIV continues to be a major driver of morbidity and mortality, particularly in sub-Saharan Africa (SSA) that is home to nearly 70% of all people living with HIV worldwide. A growing challenge for this region is the increasing number of people living with HIV and related co-infections and co-morbidities. This includes people living with HIV who are infected with another infectious pathogen (in particular but not limited to tuberculosis, malaria, genital schistosomiasis, hepatitis and human papillomavirus) as well as people living with HIV having a non-communicable disease (NCDs), in particular but not limited to cardiovascular diseases and diabetes. HIV co-infections and co-morbidities are typically associated with polypharmacy which complicates treatment decisions, increases the serious risk of drug-drug interactions and influences the effectiveness or safety of treatments. According to the World Health Organization[3], 73% of all NCD deaths are in Low- and Middle-Income Countries (LMICs) making NCDs a major cause of mortality. There is therefore an urgent need to improve prevention, treatment and clinical management of people living with HIV and related co-infections and co-morbidities by accelerating clinical research for new/improved (combination) products and clinical management practices. Given the importance of patient-centred approaches to healthcare, studies examining how prevention or treatment of non-communicable diseases can be integrated into models of care established for the management and treatment of HIV are essential.
Expected Outcomes
Proposals submitted under this topic should aim for delivering results that are directed, tailored towards and contributing to ALL of the following expected outcomes:
The proposals submitted under this topic should generate evidence on efficacy, immunogenicity, safety and/or clinical utility for healthcare professionals and clinicians in SSA of novel/improved products that aim to improve prevention and/or treatment outcomes for a co-infection or co-morbidity to HIV.
This includes the prevention of developing HIV co-morbidities or advanced HIV disease (as per WHO definition[4]). Proposals should address effective service integration in different healthcare systems in SSA, including safer polypharmacy use.
The proposals submitted under this topic should address late-stage (phase IIb and thereafter) clinical development.
The target population is people with HIV, including advanced HIV disease associated with co-morbidities and patients on long term HIV treatment (including antiretroviral and HIV control). Except for Tuberculosis (covered in other call for proposals), all infectious diseases and co-morbidities in this target population are within the scope of this topic. The clinical research may also include advanced HIV disease associated with co-morbidities. Existing high-risk co-morbidities and those attributed to the use of medications or other interventions to treat HIV are also in scope.
The research can be conducted in any age group, but it should be inclusive when relevant and ensure the participation of vulnerable research participants, for example but not limited to people living with HIV having impaired organ function. Social and societal dimensions including strategies for social inclusion and stigma mitigation are to be considered. Sex and gender differences and the effects of age should be duly taken into account when relevant. For Phase III studies, applicants are encouraged to ensure adequate statistical power for sex/gender- and age-specific analyses when relevant.
The proposals should address how the generated data will support public health authorities and policy makers to inform updated evidence-based clinical guidelines and design relevant HIV policies.
Cost-effectiveness and implementation research is within the scope of this topic, especially in the context of new innovations such long acting injectables and monoclonal antibodies. For long-acting injectables and monoclonal antibodies in particular, the implementation research should consider cost-effectiveness studies or other activities to make interventions affordable and accessible.
Epidemiological and surveillance studies with new cohorts and development or evaluation of diagnostics are out of scope of this topic. However, the continuation of surveillance of existing cohorts and the use of diagnostics as part of the standard of care when relevant is permissible.
The prevention and treatment of a HIV infection itself or clinical management exclusively focusing on HIV infection is also out of scope of this topic. The assessment of HIV parameters developing interventions for co-infections or co-morbidities or in clinical management is in scope.
Preclinical studies are considered out of scope of the topic.
However, preparatory activities conducted during the preclinical phase can be considered in scope if they enable the conduct of the clinical study/ies in scope (these activities include but are not limited to protocol writing, development/evaluation of laboratory tests, CMC related activities, etc.).
For all Global Collaboration Actions such as this topic, proposals submitted are expected to leverage financial and/or in-kind contribution from contributing partners. Proposals should define the activities of their project in its entirety, including details of the component(s) for which Global Health EDCTP3 funding is requested and the component(s) that are to be financed by contributing partners. Each contribution should be well described and budgeted in each proposal, so that the activities and related costs that are covered by the in-kind or financial contribution(s) are clearly identified.
Where possible, collaboration and coordination with the AU-EU Health Partnership’s Manufacturing and Access to Vaccines, medicines and health technologies (MAV+) hub is encouraged. The proposers could show, for example, willingness to enter into technology transfer agreements with African counterparts - including the provision of patents, technical knowledge and know-how, or early engagement with regulators or with African manufacturers to support the translation into affordable products adapted to the regional market.
When relevant, proposals should clearly describe the desired target product profile. Applicants need to concisely describe any prior relevant research findings and explain how the proposal builds on available data (including data generated in scope of earlier EDCTP programmes if available). Full details of the development milestones, including specific go/no-go criteria for the implementation of the proposed clinical trial(s) must be included, as well as specific plans for the subsequent regulatory approval process, which should aim at obtaining relevant market authorisation and an access strategy that will allow patients in low-resource settings to access the final product.
The applicants are encouraged to consider the latest innovations and advances in the clinical trial design and research methods in order to evaluate promising interventions allowing shorter development timings.
Proposals should engage communities and relevant stakeholders, most notably (local) key opinion leaders, researchers, healthcare professionals, policy makers, public health authorities and end-users. Applicants should provide methodologies for translating research findings into public health practice and policy guidelines and are encouraged to follow guidance provided in the EDCTP Knowledge Hub Research into Policy Toolkit.
Applicants are reminded of the expectation that proposals should come from research consortia with a strong representation of institutions and researchers from SSA countries, including involvement of Franco/Lusophone countries, if possible. Collaboration with other international research groups with relevant experience is very much encouraged. Applicants are also reminded of the expectation of reaching out to organisations in countries with relatively lower research capacities.
All projects funded under this topic are strongly encouraged to participate in networking and joint activities, such as external conferences, workshops or symposia for an exchange of knowledge, and best practices with external collaborators.
[1] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014
[2] The Global Health EDCTP3 Programme Office will ask the applicant contributing partner to revise the letter in case it significantly departs from the template letter published on the Global Health EDCTP3 website or is missing any compulsory elements. The final decision as to acceptance or rejection of a new contributing partner rests with the Global Health EDCTP3 Governing Board.
[3] WHO website –- Noncommunicable diseases fact sheet (23 December 2024)
[4] WHO | Global HIV Programme
1. Admissibility Conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
The conditions are described in General Annex B except for the specific conditions for the Global Health EDCTP3 JU funding as regards entities eligible for funding and consortium composition, the specific rule for countries where the coordinator may be established and the obligation to designate a scientific project leader as below.
Specific conditions replacing the relevant sections in General Annex B to the Horizon Europe Work Programmes
A. Entities eligible for funding
This section applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).
To become a beneficiary, legal entities must be eligible for funding. To be eligible for funding, applicants must be established in one of the following countries:
Legal entities which are established in countries not listed above (including in low-and middle-income countries that are not members of the EDCTP Association) will be eligible for funding if provided for in the specific call topic conditions, or if their participation is considered essential for implementing the action by the granting authority.
B. Consortium composition
Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of Global Health EDCTP3, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes as beneficiaries:
This condition applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).
For the two CSA (2) topics under call HORIZON-JU-GH-EDCTP3-2026-03 in case the applicant consortia opt for including the EDCTP Association as coordinator, the EDCTP Association must not be counted as one of the three independent legal entities necessary to ensure the eligibility of the consortium composition.
Specific cases:
Affiliated entities — Affiliated entities are eligible for funding under the same conditions as beneficiaries.
Associated partners — Entities not eligible for funding and therefore not able to participate as beneficiaries or affiliated entities (i.e. entities which participate in the action without signing the grant agreement, and without the right to charge costs or claim contributions) are allowed, subject to any conditions regarding associated partners set out in the specific call conditions.
International organisations – International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.
Specific rules regarding legal entities that may be the coordinator of an indirect action
In accordance with Article 110(2) of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17–119.]], where entities established in a third country without an agreement to protect the financial interests of the Union participate with funding in an indirect action, the coordinator of the indirect action must be established in a Member State or associated country, or South Africa.
Scientific project leader
If the coordinator is not established in a country in SSA (please see previous paragraph), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described below is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity. The scientific project leader oversees the project scientific governance and leadership. For this purpose, proposals must include a work package where the details of scientific project leadership are laid down. The scientific project leader should indicatively perform the following tasks:
Annex 1 to the grant agreement and the consortium agreement should address the relationship of the scientific project leader with the coordinator regarding their respective tasks, for example sharing of the information received from or sent to Global Health EDCTP3 on all issues of interest for the proper scientific management of the action.
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
Specific conditions related to Scores and weighting
Replacing the scores and weighting section in General Annex D to the Horizon Europe Work Programmes as regards second stage of two-stage evaluations, for Research and Innovation Actions (RIA). Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criterion 3 (Quality and Efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.
Proposals that pass the individual threshold and the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.
Nota bene: for the CSAs and the first stage of the two-stage evaluation of RIAs, the scores and weighting as indicated in Annex D of the General Annexes of the Horizon Europe work programme 2023/2025 apply.
In addition to the aspects of award criteria included in General Annex D, the following aspects are taken into consideration during the evaluation of second-stage proposals:
For the ‘impact’ criterion: Production of meaningful and significant effects enhancing the impact of the relevant research activities via the inclusion of effective in-kind and/or financial contribution of contributing partners.
For the ‘quality and efficiency of the implementation’ criterion: Leveraging of financial and/or in-kind contributions from contributing partners that are equal or greater than the requested JU contribution, in order to ensure the necessary resources and effort for the action.
are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
Implementing the provision on affordable access as defined in Article 114 of the Council Regulation 2021/2085[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17.]], grants awarded under this topic will have to include in their Plan for the exploitation and dissemination of results including communication activities to be submitted during the project as a deliverable also the following:
Access plan
Participants must include in their Plan for the exploitation and dissemination of results[[For more information on the Plan for the exploitation and dissemination of results, please consult the General Annexes of Horizon Europe Work Programmes.]] an appropriate and proportionate access plan that demonstrates their strategies to ensure that the products and services that they develop based or partly based on the results of clinical studies undertaken by their project are affordable, available and accessible to the public (market and end-users) at fair and reasonable conditions. This covers registration targets, plans to meet demand, flexible approaches to IP, engagement with regulators and manufacturers where relevant and other strategies that reflect ability to pay and ensures that economic barriers to access are low. In addition, participants should add, if relevant, as part of the plan, an outline on how to achieve the optimal use of an intervention including, for example, how to avoid irrational use, overuse or abuse (e.g. antimicrobials).
The plan is to be submitted with the second-stage proposal. In addition to any updates during the project, a final version of the Plan for the exploitation and dissemination of results including the above access plan, must also be submitted with the final report of the project.
Also in line with Article 114 of the Council Regulation 2021/2085[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014]], participants will be subject to the following additional exploitation obligations:
described in Annex G of the Work Programme General Annexes.
JU right to object to transfer/exclusive licensing
Global Health EDCTP3 may, up to four (4) years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5 of the Model Grant Agreement. In addition, in accordance with Article 24(3) of Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014, p. 17.]] and the Model Grant Agreement, the right to object applies also to participants that have not received funding from the JU.
Information sharing regarding the proposals and the evaluation results
Applicants should be aware that the following information regarding their proposals may be shared with the members of the JU Committee of the EDCTP Association:
Access to information and involvement of contributing partners
Evaluation
To promote transparency and accountability, Global Health EDCTP3 may invite any contributing partners providing financial contributions under a certain topic to propose one representative as observer to participate in the evaluation process under confidentiality safeguards. This possibility does not apply to contributing partners that are part of a consortium submitting a proposal under the relevant topic.
Documents and information
By applying under any topic, participants consent that the JU reserves the right to share information and documents relevant to their application and where applicable their grant agreement and its implementation with contributing partners as identified and providing financial contributions under the relevant topic. This information and documentation will only be shared under confidentiality safeguards for policy and monitoring purposes. They include:
Global Health EDCTP3 may consult the relevant contributing partners for the purpose of assessing the project reports and deliverables.
Other requirements
For all projects under this topic, if the coordinator is not from a country in SSA, the designation of a scientific project leader with the roles as described in the introduction is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity.
Annual Work Programme 2026
Global Health EDCTP3 Calls for proposals
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Note: despite blind evaluation being mentioned in the standard application form for stage 1 proposals of the two-stage calls available in the Funding and Tenders Portal (at the stage of adoption of this Work Programme), please note that the calls included in this WP are not part of the ‘blind evaluation pilot’, therefore no anonymisation is required for stage 1 proposals of the two-stage calls.
Standard application form (HE RIA IA Stage 1)
Evaluation form templates — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA and CSA Stage 1)
Guidance
HE Programme Guide 
Model Grant Agreements (MGA)
HE MGA 
Call-specific instructions 
Information on clinical studies (HE) 
Additional documents:
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 4. Health
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual 
Funding & Tenders Portal Terms and Conditions 
Funding & Tenders Portal Privacy Statement
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.